LOS ANGELES, CA, Jan. 11, 2018 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a clinical-stage developer of non-invasive electroceuticals for the treatment of central nervous system (CNS) disorders, today announced it is working with ShareIntel – Shareholder Intelligence Services to continue its commitment to protecting its shareholders and maximizing shareholder value. ShareIntel offers unprecedented access and insight into broker-dealer, clearing firm and shareholder position movement. ShareIntel utilizes a patented process called DRIL-DownTM to aggregate and analyze historic repository data from reporting entities, broker-dealers, and shareholders. This will enable Endonovo to proactively track equity flows, identify parties to suspicious, aberrant and/or unusual trading activity and deploy action steps to help curtail such activity.
“We have noticed certain irregularities involving both market makers and clearing firms” said Endonovo CEO, Alan Collier. “Utilizing ShareIntel’s patented processes and proprietary analytics will enable The Company to investigate these matters in addition to tracking equity flows and identify any suspicious, aberrant and or unusual trading activity.”
David Wenger, President & CEO of ShareIntel said, “ShareIntel tracks and monitors critical broker-dealer and shareholder movement. We look forward to helping Endonovo DRIL-DownTM to identify parties to suspicious trade settlement imbalances, maximize shareholder ownership transparency and facilitate effective shareholder outreach”.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a clinical-stage developer of non-invasive electroceuticals for the treatment of Central Nervous System (CNS) Disorders, including traumatic brain injury and multiple sclerosis. The Company’s non-invasive electroceuticals use targeted-Pulsed Electromagnetic Fields (tPEMF) to induce micro-currents in tissues to target proinflammatory, fibrogenic and regenerative signaling pathways for the treatment of cardiovascular and cerebrovascular diseases, as well as for the treatment of chronic kidney and liver disease. Endonovo Therapeutics’ is developing a pipeline of electroceutical-based therapies for the treatment of cardiovascular disease, cerebrovascular disease, peripheral artery disease, chronic kidney disease, and non-alcoholic steatohepatitis (NASH). The Company’s tPEMF technology using short wave radiofrequency at 27.12 MHz has been FDA-cleared and has a CE Mark for the treatment of soft tissue injuries and post-operative pain and edema, as well as CMS National Coverage for the treatment of chronic wounds. Endonovo is developing a clinical pipeline using tPEMF for the treatment of central nervous system (CNS) disorders, including post-concussion syndrome, mild traumatic brain injury (mTBI), acute sports-related concussions and multiple sclerosis.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
